@article{0060945281ad4771a51902e8fc3e51dd,
title = "The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settings",
abstract = "The iCannToolkit is a first important step to systematically gather evidence regarding the health effects of contemporary medical and non-medical cannabis use—over time, among licit and illicit settings, cultures and age groups—in order to inform policy development and to raise awareness concerning cannabis use-related risks and benefits.",
keywords = "Assessment, cannabis, dose, iCannToolkit, international cannabis toolkit, measurement, standardization",
author = "Valentina Lorenzetti and Chandni Hindocha and Kat Petrilli and Paul Griffiths and Jamie Brown and {\'A}lvaro Castillo-Carniglia and Caulkins, {Jonathan P.} and Amir Englund and ElSohly, {Mahmoud A.} and Gage, {Suzanne H.} and Teodora Groshkova and Antoni Gual and David Hammond and Will Lawn and Hugo L{\'o}pez-Pelayo and Jakob Manthey and Claire Mokrysz and {Liccardo Pacula}, Rosalie and {van Laar}, Margriet and Ryan Vandrey and Elle Wadsworth and Adam Winstock and Wayne Hall and Curran, {H. Valerie} and Freeman, {Tom P.}",
note = "Funding Information: This study was supported by the Society for the Study of Addiction, European Monitoring Centre for Drugs and Drug Addiction. H.L.P. works under the CERCA Programme/Generalitat de Catalunya and receives funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III through a {\textquoteleft}Juan Rodes{\textquoteright} contract (JR19/00025). V.L. was supported by a Val & Al Rosenstrauss Senior Research Fellowship and by an Australian Catholic University competitive Scheme. A.C.C. received funding from ANID—Millennium Science Initiative Program, no. NCS2021_003 and no. NCS2021_013. Funding Information: A.G. received funding from Novartis for work outside this area (a phase III cocaine trial). A.E. has received speaker a honorarium from GW Pharmaceuticals. A.W. is the founder of the Global Drug Survey. C.H. became a full‐time employee of GW Pharmaceuticals after the consensus meeting. D.H. has served as a paid expert witness on behalf of public health authorities in Canada in response to legal challenges from the cannabis industry. H.L. has received honoraria and travel grants from Janssen and Lundbeck. J.B. has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications (Pfizer and J&J). R.V. receives consulting fees for Canopy Health Innovations and Syqe Medical Ltd, and is on the Scientific Advisory Board for MyMD Pharmaceuticals and Artiam Bio Inc. V.C. has consulted for Janssen. V.L., W.H., T.P.F., E.W., T.G., W.L., A.C.C., J.P.C., R.L.P., M.v.L., K.P., P.G., M.A.E., S.H.G., J M. and C M. have no competing interests to declare. Funding Information: This study was supported by the Society for the Study of Addiction, European Monitoring Centre for Drugs and Drug Addiction. H.L.P. works under the CERCA Programme/Generalitat de Catalunya and receives funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III through a ?Juan Rodes? contract (JR19/00025). V.L. was supported by a Val & Al Rosenstrauss Senior Research Fellowship and by an Australian Catholic University competitive Scheme. A.C.C. received funding from ANID?Millennium Science Initiative Program, no. NCS2021_003 and no. NCS2021_013.",
year = "2022",
month = jun,
doi = "10.1111/add.15855",
language = "English",
volume = "117",
pages = "1523--1525",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",
}
